Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
41
ULBI Quote, Financials, Valuation and Earnings
Last price:
$7.19
Seasonality move
:
8.02%
Day range:
$7.17 - $7.38
52-week range:
$6.36 - $13.39
Dividend yield:
0%
P/E ratio:
13.11x
P/S ratio:
0.73x
P/B ratio:
0.89x
Volume:
38.8K
Avg. volume:
59.6K
1-year change:
1.98%
Market cap:
$119.9M
Revenue:
$158.6M
EPS (TTM):
$0.55
Analysts' Opinion
-
Consensus RatingUltralife has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Ultralife has an estimated upside of 94.18% from its current price of $7.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.21.
Fair Value
-
According to the consensus of 0 analysts, Ultralife has 94.18% upside to fair value with a price target of -- per share.
ULBI vs. S&P 500
-
Over the past 5 trading days, Ultralife has underperformed the S&P 500 by -9.37% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ultralife does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ultralife revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ultralife reported revenues of $35.7M.
Earnings Growth
-
Ultralife earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ultralife reported earnings per share of $0.02.
Enterprise value:
121.1M
EV / Invested capital:
0.85x
Price / LTM sales:
0.73x
EV / EBIT:
9.62x
EV / Revenue:
0.73x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
8.85x
Price / Operating cash flow:
8.77x
Enterprise value / EBITDA:
7.32x
Gross Profit (TTM):
$43.1M
Return On Assets:
5.13%
Net Income Margin (TTM):
5.44%
Return On Equity:
6.98%
Return On Invested Capital:
6.07%
Operating Margin:
1.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $119.5M | $150.2M | $165.2M | $39.5M | $35.7M | |
| Gross Profit | $26.6M | $35.9M | $43.1M | $9.8M | $8.7M | |
| Operating Income | -$1.3M | $6M | $12.1M | $2.1M | $511K | |
| EBITDA | $3.6M | $11.4M | $16.5M | $3.3M | $1.5M | |
| Diluted EPS | -$0.06 | $0.26 | $0.55 | $0.08 | $0.02 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $62.2M | $64.5M | $78.9M | $89.6M | $86.4M | |
| Total Assets | $135.6M | $136.8M | $167.9M | $176.1M | $172.4M | |
| Current Liabilities | $17.4M | $16.7M | $28.1M | $26.4M | $26.2M | |
| Total Liabilities | $21.7M | $18.3M | $52.6M | $54.4M | $37.8M | |
| Total Equity | $113.8M | $118.5M | $115.3M | $121.8M | $134.6M | |
| Total Debt | $3.7M | $253K | $22.9M | $26.1M | $7.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8M | $2.1M | $16M | -$889K | $4.7M | |
| Cash From Investing | -$25.4M | -$1.8M | -$2.3M | -$534K | -$594K | |
| Cash From Financing | $22.7M | $4.2M | -$16.1M | $2.4M | -$4.1M | |
| Free Cash Flow | -$9.9M | $231K | $13.7M | -$1.4M | $4.2M | |
ULBI
Sector
Market Cap
$119.9M
$764.1M
Price % of 52-Week High
53.85%
78.36%
Dividend Yield
0%
0%
Shareholder Yield
--
2.32%
1-Year Price Total Return
1.98%
-1.72%
Beta (5-Year)
0.947
0.899
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.55
200-day SMA
Sell
Level
$9.73
Bollinger Bands (100)
Sell
Level
7.91 - 10.05
Chaikin Money Flow
Sell
Level
-7.5M
20-day SMA
Sell
Level
$7.66
Relative Strength Index (RSI14)
Sell
Level
35.26
ADX Line
Sell
Level
19.93
Williams %R
Buy
Level
-96.1165
50-day SMA
Sell
Level
$8.11
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
47.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4891)
Buy
CA Score
(Annual)
Level (1.0877)
Buy
Beneish M-Score
(Annual)
Level (-2.2222)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.4449)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
Stock Forecast FAQ
In the current month, ULBI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ULBI average analyst price target in the past 3 months is --.
-
Where Will Ultralife Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ultralife share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Ultralife?
Analysts are divided on their view about Ultralife share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ultralife is a Sell and believe this share price will drop from its current level to --.
-
What Is Ultralife's Price Target?
The price target for Ultralife over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ULBI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ultralife is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ULBI?
You can purchase shares of Ultralife via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ultralife shares.
-
What Is The Ultralife Share Price Today?
Ultralife was last trading at $7.19 per share. This represents the most recent stock quote for Ultralife. Yesterday, Ultralife closed at $7.21 per share.
-
How To Buy Ultralife Stock Online?
In order to purchase Ultralife stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 0.85% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.91% over the past day.
